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Summary 
Objective: Patients with mutations of NKB and its receptor show hypogonadotrophic hypogonadism, 
but there is little evidence for the importance of this pathway in reproductive function in normal 
men, or its functional hierarchy with kisspeptin. 
Design: An open label study wherein men (n=6) were administered the NK3R antagonist MLE4901 
40mg orally twice a day for 7 days. Kisspeptin-10 (0.3 µg/kg iv bolus) was given before and on day 7 
of NK3R antagonist treatment.  
Patients: Subjects were healthy men.  
Measurements: Reproductive hormones were measured before and during the NK3R antagonist 
administration, including frequent sampling on two occasions for analysis of pulsatile LH secretion.   
Results: LH, FSH and testosterone secretion were decreased during NK3R antagonist administration.   
LH showed a biphasic response, being reduced after 24 hours of treatment (4.5±0.6 IU/l pre-
treatment to 1.7±0.2 IU/l, p<0.05), with partial recovery thereafter; but it was again decreased on 
day 7 (2.5±0.6 IU/l, p<0.05 vs pre-treatment).  FSH secretion was also suppressed, with a similar 
temporal pattern to that of LH. Testosterone secretion was decreased from 24 hours (18.4±1.6 pre-
treatment vs 5.6±1.5 nmol/l, p<0.01) and remained suppressed throughout the treatment period. 
Analysis of LH pulsatility showed that both basal and pulsatile LH secretion were markedly 
suppressed but there was no detected change in LH pulse frequency.  Kisspeptin-10 stimulated LH 
secretion, with similar responses before and during NK3R antagonist administration. 
Conclusions: These data demonstrate a central role for NKB/NK3R in the physiological regulation of 
reproductive function in men, and that this is functionally upstream of kisspeptin-mediated GnRH 
secretion.   
 
Key words (7 words): Neurokinin B, Kisspeptin, GnRH pulsatility, Gonadotropins, Testosterone 
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Introduction 
Kisspeptin and neurokinin B (NKB) are hypothalamic neuropeptides now recognised to be key 
regulators of GnRH secretion and thus central to the control of the human hypothalamo-pituitary-
gonadal (HPG) axis (Skorupskaite et al. 2014). Men and women with loss-of-function mutations in 
kisspeptin, neurokinin B or their cognate receptors (KISS1R and NK3R) show reduced GnRH secretion 
and hypogonadotropic pubertal delay (de Roux et al. 2003; Seminara et al. 2003; Topaloglu et al. 
2009; Topaloglu et al. 2012), whilst activating mutations in the kisspeptin receptor are associated 
with precocious puberty (Teles et al. 2008).  
Whilst kisspeptin potently stimulates gonadotropin secretion (George et al. 2011; Dhillo et al. 2005; 
Jayasena et al. 2015; Jayasena et al. 2011; Chan et al. 2011) and increases LH pulse frequency in men 
(George et al. 2011), the effects of exogenous NKB administration are unclear. In animal studies, 
both stimulatory and inhibitory actions of NKB on LH secretion has been observed (Billings et al. 
2010; Navarro, Castellano, et al. 2011; Ramaswamy et al. 2011), whilst it had no effect on 
reproductive hormone concentrations or LH pulsatility when infused for 8 hours to healthy men and 
women (Jayasena et al. 2014).  Administration of the NK3R antagonist ESN364 to normal men 
suppressed LH and testosterone but not FSH secretion (Fraser et al. 2016). However, the effect on 
LH lasted only few hours with recovery to baseline within 24 hours (Fraser et al. 2016). Antagonism 
of NK3R has been shown to decrease LH secretion and reduce the frequency of LH pulses in women 
with PCOS (George et al. 2016) and in gonadectomised animals (Li et al. 2015; Fraser et al. 2015), 
indicating a role for NKB-NK3R signalling in the regulation of pulsatile GnRH and thus LH secretion.  
Kisspeptin and NKB are co-expressed by some neurones within the hypothalamus, in humans and 
other species. These neurones can also co-express the opioid dynorphin and thus have been termed 
KNDy neurones (Cheng et al. 2010). The interaction and functional hierarchy between kisspeptin and 
neurokinin B are inferred from observations from preclinical and clinical studies. Thus in animal 
models, Kissr1 knockout mice were unable to show a stimulatory effect of the NK3R agonist senktide 
on LH secretion (Garcia-Galiano et al. 2012), and in juvenile male monkeys, kisspeptin-10 stimulated 
LH secretion after desensitization with senktide infusion (Ramaswamy et al. 2011). These results 
suggest the action of NKB is upstream of kisspeptin. This is supported by studies in patients with 
inactivating genetic defects in NKB (TAC3) and its NK3 receptor (TAC3R), showing slow GnRH 
secretion as inferred from low LH secretion, in whom kisspeptin-10 increased LH pulse frequency 
(Young et al. 2013). Women treated with an NK3R antagonist in a model of the mid-cycle LH surge 
showed largely preserved LH response to kisspeptin administration, although there were effects on 
timing and duration and the relationship to circulating estradiol concentrations was lost 
(Skorupskaite et al. 2016), providing evidence that neurokinin B is functionally upstream of 
kisspeptin in the regulation of GnRH secretion in healthy women.  
We therefore sought to determine whether NKB has a physiological role in the regulation of the 
male reproductive axis by the administration of the specific NK3R antagonist MLE4901, with detailed 
analysis of potential effects on GnRH/LH pulsatility, and to explore the hierarchy between NKB and 
kisspeptin in the control of this pathway.  
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Materials and Methods   
Study subjects 
Six healthy men, aged 23-39 years were recruited to this study; all volunteers provided informed 
written consent and the study received Ethics Committee approval. Subjects had normal physical 
examination and serum LH, FSH and testosterone concentrations, and full blood count, renal 
function, electrolytes, liver function and electrocardiogram were within normal limits.  
Study drugs 
The NK3R antagonist MLE4901 (previously known as AZD4901, kindly provided by AstraZeneca) was 
administered orally at 40 mg twice daily. It has been shown to completely block neurokinin B agonist 
senktide induced calcium influx in human NK3R expressing Chinese hamster ovary cells with high 
selectivity (Malherbe et al. 2011). This dose of MLE4901 reduced LH secretion and pulse frequency 
in normal women (Skorupskaite et al. 2016) and in women with Polycystic Ovary Syndrome (George 
et al. 2016). Kisspeptin-10 was administered by an intravenous bolus at 0.3 µg/kg as previously 
described (George et al. 2011), with the dose chosen as the lowest that caused maximal stimulation 
in LH secretion (George et al. 2011).  
Protocol 
Investigation of the effect of NK3R antagonism on gonadotropin and testosterone secretion.  
A schematic representation of the protocol is shown in Figure 1. Volunteers were administered the 
NK3R antagonist for 7 days. Single time point daily peripheral venous blood was sampled for LH, FSH 
and testosterone measurement between 08.00 and 10.00 hours at 24 hours before treatment 
started (day -1), and on days 2, 4, 6 and 7 of NK3R antagonist administration. During treatment, the 
daily blood sampling was performed immediately prior to the next dose of NK3R antagonist, i.e. 12 
hours after the previous dose.  
Investigation of the effect of NK3R antagonist on LH pulsatility.  
On day -1 and on the last day of NK3R antagonist administration (day 7) volunteers attended our 
clinical research facility for 8 hours. On day 7, volunteers took the NK3R antagonist within an hour 
before starting the pulsatility assessment blood sampling. All visits commenced between 08.00 and 
09.00 hours. Blood samples were collected via an indwelling intravenous cannula at 10 min intervals 
for 6 hours for assessment of LH pulsatility.  
Establishment of the hierarchy between kisspeptin and neurokinin B in the regulation of LH secretion.  
Kisspeptin-10 was administered at 6 hours of the pulsatility study described above, with blood 
sampling every 10 minutes for 2 hours after administration.  
Safety blood tests including full blood count, renal function, electrolytes, and liver function were 
checked before commencing MLE4901, at the end of 7-day treatment and 2-3 weeks later. Post-
treatment testosterone concentrations were measured 2 weeks after treatment. 
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Hormone assays 
Blood samples were centrifuged and serum frozen at -20°C or below until analysis. LH and FSH were 
measured by ELISA as previously described (George et al. 2011). Testosterone was measured by 
liquid chromatography-tandem mass spectrometry. LH pulsatility was assessed by deconvolution 
analysis on blinded data with ApEn quantified as a measure of secretory regularity (Liu et al. 2009). 
Statistical analysis 
Mean LH, FSH and testosterone concentrations over time were compared using one-way analysis of 
variance (ANOVA) with repeated-measures followed by Bonferroni’s post hoc correction for multiple 
comparisons. Area under the curve (AUC) of LH during frequent sampling was determined by 
trapezoid integration on day -1 (control) and on day 7 of NK3R antagonist administration, and the 
change in AUC LH during one hour pre kisspeptin-10 injection and for the 2 consecutive hours 
thereafter was calculated. Comparisons across both time and between treatments were performed 
using repeated-measures two-way ANOVA with Bonferroni’s multiple comparisons post hoc analysis. 
Paired Student’s t-test (for parametric data) or Wilcoxon matched-pairs signed rank test (for non-
parametric data) were used to assess changes in measures of LH pulsatility. Data are presented as 
mean ± SEM. 
Ethical approval 
The study protocol was approved by South East Scotland Research Ethics Committee (Ref: 
09/S1101/67). 
 
Results 
NK3R antagonist decreases gonadotropin and testosterone secretion 
LH secretion based on daily LH values decreased during NK3R antagonist administration (p<0.03), 
with a biphasic response: LH concentrations were significantly reduced after 24 hours of treatment 
(4.5±0.6 IU/l on day -1 to 1.7±0.2 IU/l on day 2, p<0.05), then recovered (4.2±0.7 IU/l on day 4 and 
3.7±0.7 IU/l on day 6) but were again decreased on day 7 (2.5±0.6 IU/l vs day -1, p<0.05) (Fig. 2A). To 
detect subtle changes in hormone secretion over time potentially overlooked by performing single 
time blood sampling, a more detailed analysis of LH secretion every 10 minutes for 6 hours post 
NK3R antagonist dose on day 7 of treatment showed a decrease in LH AUC throughout the 6 hours 
post-treatment compared to day -1 (16.8±2.7 vs 8.7±1.5 IU/l over 6hr with NK3Ra, p=0.0007, Fig. 
2B). 
FSH secretion was also suppressed during NK3R antagonist administration (p=0.001), being 
significantly lower after 24 hours of treatment (3.6±0.3 vs 2.4±0.4 IU/l, p<0.001) (Fig. 2C). FSH 
showed a comparable pattern to changes in LH over the following days, being significantly lower 
than day -1 on days 2, 4 and 7 (each p<0.05 vs day -1) but not on day 6 of NK3R antagonist 
administration.  
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Testosterone secretion declined rapidly in response to NK3R antagonist at 24 hours (18.4±1.6 day-1 
vs 5.6±1.5 nmol/l, p<0.01) but in contrast to LH, was consistently suppressed for the remainder of 
the treatment period (p<0.05 on days 4, 6 and 7 vs day -1) (Fig. 2D). Serum testosterone recovered 
to pre-treatment concentrations in all subjects 2 weeks later (19.8±2.0 nmol/l).  
Effect of NK3R antagonist on pulsatile LH secretion in men 
The characteristics of the pulsatile secretion of LH were determined before and after 7 days of NK3R 
antagonist treatment. The LH pulse profile from all individual subjects is shown in figure 3. LH pulse 
frequency was unchanged by NK3R antagonist (0.50±0.09 vs 0.47±0.07 pulses/hr, ns) (Fig. 4A). 
However, consistent with the overall suppression of LH secretion seen in the daily time point 
analysis, other parameters of LH secretion were reduced. Both basal (nonpulsatile) and pulsatile 
mass of LH secretion were lower with NK3R antagonist treatment compared with day -1 (Fig. 4B-C, 
both p=0.02). The secretory mass of LH per pulse (Fig. 4D) was not significantly changed (p<0.09). 
NK3R antagonist increased the orderliness of the LH secretion pattern as assessed by approximate 
entopy (ApEn) (p=0.02; Fig. 4E).  
NK3R antagonist does not reduce kisspeptin-induced LH secretion 
To assess the hierarchical interaction between kisspeptin and neurokinin B in the regulation of LH 
secretion in men, an intravenous bolus injection of kisspeptin-10 was administered after 6 hours of 
blood sampling on day-1 and on day 7 of NK3R antagonist treatment (Fig. 5). Kisspeptin-10 elicited a 
rapid increase in LH concentration (3.0±0.6 at 6 hours vs 4.8±0.5 IU/L at 7 hours, p<0.05 and AUC LH 
2.7±0.4 at 6 hours vs 5.2±0.5 IU/l hr at 7 hours, p<0.01; Fig. 5A-B). The stimulation of LH secretion by 
kisspeptin-10 was maintained in the presence of NK3R antagonist (mean LH and AUC LH for 
kisspeptin-10+NKB antagonist: at 6 hours vs at 7 and 8 hours, both p<0.01; Fig. 5A-B) and stimulated 
LH concentrations were similar to those after kisspeptin-10 alone (AUC LH at 7 and 8 hours 
kisspeptin-10: 5.2±0.5 and 3.9±0.4 vs 5.2±0.7 and 4.0±0.6 IU/l hr with NK3R antagonist, ns). 
However, calculation of the LH response to kisspeptin-10 as ΔAUC over the 2 hours following 
administration suggested an enhanced response during NK3R antagonist treatment (kisspeptin-10 
alone ΔAUC LH 7 and 8 hours: 2.5±0.2 and 1.2±0.2, vs kisspeptin-10 with NK3R antagonist 3.8±0.5 
and 2.5±0.4,  both p<0.05; Fig. 5C) reflecting the lower LH concentrations with the NK3R antagonist 
at the time of kisspeptin administration with similar LH concentrations after administration of 
kisspeptin with and without the NK3R antagonist.  
Tolerability and safety 
MLE4901 treatment was well tolerated. One man reported reduced libido whist on NK3R antagonist 
and this recovered after the completion of the study. Haematology and biochemistry safety 
parameters remained stable in all subjects throughout the study period.  
 
Discussion 
The present study investigated the role of neurokinin B in the control of the reproductive axis in 
healthy men and its interaction with kisspeptin in the regulation of GnRH secretion, using LH as a 
surrogate. Pharmacological blockade of NKB-NK3R signalling caused a rapid and marked decrease in 
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LH, FSH and testosterone secretion. However, the stimulatory LH response to kisspeptin after 7 days 
of NK3R antagonist was maintained. NK3R antagonism did not affect the frequency of LH pulses in 
men, but other aspects of the pulsatile nature of LH secretion were markedly reduced. These data 
provide novel evidence that NKB is a major regulator of the physiological regulation of GnRH/LH and 
testosterone secretion in men.  They also support a predominantly hierarchical relationship whereby 
central action of neurokinin B is proximal to kisspeptin in the modulation of GnRH/LH secretion, as 
previously indicated in non human primates (Ramaswamy et al. 2011), in men with NKB/NK3R 
mutations (Young et al. 2013), and in healthy women (Skorupskaite et al. 2016). 
These data demonstrate that in men, NK3R antagonist administration decreased LH secretion in a 
biphasic pattern, with a marked reduction after 24 hours administration (on day 2), and on day 7. 
Consistent with this being by suppression of GnRH secretion, NK3R antagonist also lowered FSH 
concentrations on days 2, 4 and 7 of treatment, albeit to a lesser extent than LH secretion. NK3R 
antagonists have been reported to suppress LH secretion in ovariectomised ewes (MRK-08) and 
castrate monkeys (ESN364) (Li et al. 2015; Fraser et al. 2015) but with only a transient effect in 
normal men (ESN364) (Fraser et al. 2016) without suppression of FSH secretion in either men (Fraser 
et al. 2016) or castrate monkeys (Fraser et al. 2015). This may reflect the greater effect on LH (and 
by inference GnRH) observed with MLE4901 at 40 mg BD than with the other antagonists 
investigated.   
Sustained suppression of testosterone secretion was observed throughout the 7 days of treatment. 
Previously administration of this NK3R antagonist, MLE4901, reduced both LH and testosterone 
secretion in women with PCOS after 7 days (George et al. 2016). The simultaneous decrease in 
serum LH and testosterone concentrations within 24 hours of treatment suggests a central role of 
neurokinin B in the regulation of GnRH/LH secretion, which is further supported by changes in the 
pattern of LH pulsatility. It is possible that recovery of suppressed LH secretion while testosterone 
levels remain low on days 4 and 6 may indicate a direct gonadal effect of the NK3R antagonist, as 
NKB-NK3R mRNA has been detected in human granulosa cells (Garcia-Ortega et al. 2014; Cejudo 
Roman et al. 2012). However, NKB-NK3R mRNA has not been reported in human testis. It is however 
plausible that the initial fall in testosterone results in reduced negative feedback with a secondary 
recovery in LH secretion, although caution must be taken when interpreting those findings given 
that once only daily blood sampling may miss subtle changes in hormone secretion especially when 
there are relatively rapid changes in steroid feedback and the pathways that mediate that feedback 
are likely to be impacted by this drug. Nevertheless, analysis over 6 hours after dosing on day 7 
showed consistent suppression of LH suggesting that suppression would persist with chronic 
antagonism of NKB-NK3R signalling.  FSH secretion is less sensitive to rapid changes in GnRH 
secretion, which may account for the slightly different profile of the FSH response to NK3R 
antagonism over the 7 days of treatment. 
The present study has shown that in normal men NK3R antagonist administration markedly reduced 
both basal (i.e. nonpulsatile) LH secretion and the total amount of LH secreted in pulses, 
contributing to overall lower serum LH concentrations. The regularity of the LH secretory pattern 
and by inference GnRH secretion, showed greater orderliness, as indicated by reduced ApEn. NK3R 
antagonist did not alter the frequency of LH pulses, although the ability to detect a change in LH 
pulse frequency may have been limited by the small number of men studied here, and the limited 
duration of frequent sampling. This contrasts with data from administration of the same NK3R 
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antagonist to women with PCOS (George et al. 2016) and to normal women in a model of the LH 
surge (Skorupskaite et al. 2016) and to administration of different NK3R antagonists (MRK-08 and 
ESN364) to ovariectomised ewes (Li et al. 2015; Fraser et al. 2015), where reductions in LH pulse 
frequency were demonstrated. This may however reflect sexual dimorphism in that changes in the 
frequency of LH pulses are not seen in male reproduction (Veldhuis et al. 2012), unlike the changes 
in LH pulse frequency that characterise (but are not essential for) the normal menstrual cycle(Filicori 
et al. 1986; Hurley et al. 1984). Sexual dimorphism is well recognised in the kisspeptin-induced LH 
response, with a marked increase in LH in men but a variable response in women dependent on the 
sex-steroid milieu (Dhillo et al. 2007; George et al. 2012). The female hypothalamus has significantly 
more kisspeptin cell bodies and fibres compared to men (Hrabovszky et al. 2010), and there is a 
greater abundance of neurokinin B-expressing neurones in ewes than rams (Goubillon et al. 2000), 
indicating gender differences in the NKB-kisspeptin pathway. Testosterone is also a regulator of LH 
pulse frequency in men (Veldhuis et al. 2008), thus the fall in serum testosterone is likely to have 
counteracted any suppressive effect of NK3R antagonism on LH pulse frequency. Nevertheless, the 
changes in LH secretion induced by the NK3R antagonist in this study, in concordance with a 
stimulatory action of neurokinin B and an inhibitory action of NK3R antagonist on LH pulses in 
animal studies (Li et al. 2015; Fraser et al. 2015), supports the notion that neurokinin B acts centrally 
to modulate pulsatile GnRH secretion in men and that there are complex neurokinin B/kisspeptin 
interactions that result in the characteristics of the pulsatile secretion of GnRH and thus LH.  
Kisspeptin-10 stimulated LH secretion in the presence of NK3R antagonist in normal men. This 
supports findings from animal and human studies, in particular the demonstration that kisspeptin-10 
infusion restored pulsatile LH secretion in men and women with inactivating mutations in neurokinin 
B pathway (Young et al. 2013) and in normal women in a model of the mid-cycle LH surge 
(Skorupskaite et al. 2016), that neurokinin B signalling is functionally upstream of kisspeptin.  There 
was a greater change in LH secretion in response to kisspeptin-10 in the presence of the NK3R 
antagonist, but this is likely to reflect the lower basal LH concentrations following 7 days of NK3R 
antagonist administration. There was no difference in mean LH levels after kisspeptin-10 
administration alone or following NK3R antagonist treatment. NKB may modulate kisspeptin action 
by altering the sensitivity of GnRH neurones to the latter and/or by acting on GnRH terminals 
enhancing, either synergistically or additively, kisspeptin effects. Although NKB/Kp immunoreactive 
terminals are in close apposition to GnRH terminals in the median eminence (Burke et al. 2006), no 
NK3R expression on GnRH neurones has been showed in mice and ewes (Amstalden et al. 2010; 
Navarro, Gottsch, et al. 2011). Direct action of NKB on GnRH neurones therefore seems unlikely. 
Conversely, co-infusion of neurokinin B itself and kisspeptin-54 in healthy men stimulated 
gonadotropin and testosterone secretion significantly less than with kisspeptin-54 alone and had no 
effect on LH pulsatility (Narayanaswamy et al. 2016). As reductions in GnRH and Kiss1r mRNA were 
observed after administration of the NKB agonist senktide in rats (Grachev et al. 2012), it was 
proposed that NKB can act to inhibit GnRH and kisspeptin transcription to reduce the stimulatory 
action of kisspeptin on gonadotropins (Narayanaswamy et al. 2016). Gonadotropin inhibitory 
hormone (GnIH) also appears to be upstream of kisspeptin, having no suppressive effect on 
kisspeptin-induced LH secretion in a recent study in men (George et al. 2017), although its 
interaction with neurokinin B on modulating GnRH secretion remains unknown.  While it is possible 
that NKB exerts variable stimulatory and/or inhibitory downstream actions on kisspeptin signalling, 
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perhaps in response to the sex steroid feedback environment, the present data clearly support a 
stimulatory role of NKB signalling in the normal male HPG axis.  
The present study has strengths in that a specific neurokinin-3 receptor antagonist was used, 
detailed LH pulse profiling was performed with blinded pulse analysis, and paired data were 
obtained for the control period and during administration of NK3R antagonist. The lack of 
suppression in the frequency of LH pulses by the NK3R antagonist in men is in contrast to the same 
dose of MLE4901 reducing LH pulse frequency in women with PCOS (George et al. 2016) and in 
normal women (Skorupskaite et al. 2016), which may reflect sexual dimorphism. However, the 
sample size is small and a placebo control was not employed in this mechanistic exploratory study.  
In summary, we have shown that NK3R antagonism resulted in suppression of both LH and FSH 
concentrations, and a sustained decrease in testosterone secretion in healthy men over a 7 day 
period, indicating an important role for neurokinin B in the physiological regulation of the male HPG 
axis.  We showed that the NK3R antagonist reduced some aspects of pulsatile LH secretion in men. 
Assessment of the interaction between neurokinin B and kisspeptin showed that LH response to 
kisspeptin was maintained in the presence of NK3R antagonist, supporting a functionally hierarchical 
relationship of neurokinin B being predominantly proximal to kisspeptin. These data thus indicate 
that neurokinin B modulates GnRH/LH secretion in men, with potential for therapeutic development 
as well as exploration of its contribution to disorders of reproductive function. 
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Figures: 
Figure 1. Study protocol. 6 healthy men were administered the NK3R antagonist MLE4901 orally for 
7 days. LH, FSH and testosterone were measured on days -1, 2, 4, 6 and 7 during the study. LH 
pulsatility was assessed for 6 hours on day -1 and on day 7, the last day of NK3R antagonist 
treatment. Kisspeptin (KP)-10 was administered by intravenous bolus at 6 hours with further 
frequent blood sampling for 2 hours on day -1 and day 7. 
 
Figure 2. LH, FSH and testosterone response to administration of NK3R antagonist in healthy men 
(n=6). (A) Mean of daily LH concentrations during 7 days of NK3R antagonist treatment and (B) LH 
AUC during 6 hours of 10 minute LH sampling on day-1 and on day 7 of NK3R antagonist 
administration. Mean FSH (C) and testosterone (D) response to NK3R antagonist administration. 
Data are presented as mean ± SEM. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 vs day -1. 
 
Figure 3. LH profiles sampled at 10 min intervals from 6 individual subjects on control day -1  (black 
circles) and on day 7 of NK3Ra administration (open circles). Arrows indicate LH pulses detected by 
blinded deconvolution with (open arrows) and without (black arrows) NK3R antagonist treatment. 
 
Figure 4. Analysis of 6 hour LH secretory pattern on day 7 of NK3R antagonist treatment compared 
to control day -1 in healthy men. Mean LH pulse frequency (A), basal (nonpulsatile) LH secretion (B), 
pulsatile LH secretion (C), LH secretory mass per pulse (D) and the relative orderliness/regularity of 
LH secretory pattern (E) on day 7 of NK3R antagonist treatment compared to day -1. Data are 
presented as mean ± SEM. *, p=0.02. 
 
Figure 5. LH response to kisspeptin-10 injection with and without NK3R antagonist pre-treatment 
in healthy men. (A) Mean LH concentrations from 5 to 8 hours of frequent sampling following 
kisspeptin-10 administration at hour 6;  (B) AUC LH and (C) ΔAUC LH were compared over one hour 
before kisspeptin-10 administration (hour 6), with 2 hours post kisspeptin-10 administration (hours 
7 and 8), with (day 7) and without (day -1) NK3R antagonist pre-treatment during frequent blood 
sampling for LH every 10 minutes. Data are presented as mean ± SEM. *, p<0.05; **, p<0.01; ****, 
p<0.0001. 
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